Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Core Insights - The company is focusing on three key strategic areas for capital allocation, with an emphasis on its commercial product, Vafseo, to establish it as the standard of care [1] - There are ongoing Phase IV/IIIb trials aimed at generating data necessary for Vafseo to become the standard of care [1] - The company is committed to advancing its initiatives in kidney disease [2]